Search results for "COPD"

showing 10 items of 483 documents

Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression.

2017

Toll-like receptors (TLRs) and nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) are two major forms of innate immune sensors but their role in the immunopathology of stable chronic obstructive pulmonary disease (COPD) is incompletely studied. Our objective here was to investigate TLR and NLR signalling pathways in the bronchial mucosa in stable COPD.Using immunohistochemistry, the expression levels of TLR2, TLR4, TLR9, NOD1, NOD2, CD14, myeloid differentiation primary response gene 88 (MyD88), Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP), and the interleukin-1 receptor-associated kinases phospho-IRAK1 and IRAK4 were measured in the bronchial muc…

0301 basic medicineTIRAPMaleRespiratory SystemVital CapacityHAEMOPHILUS-INFLUENZAELUNG MICROBIOMEPathogenesisPulmonary Disease Chronic Obstructive0302 clinical medicineNOD2ImmunopathologyForced Expiratory VolumeNod1 Signaling Adaptor ProteinNOD1PhosphorylationCOPDSmoking11 Medical And Health SciencesMiddle AgedCPG-DNAbronchial inflammationAnti-Bacterial AgentsStreptococcus pneumoniaePseudomonas aeruginosaMOUSE LUNGFemaleLife Sciences & BiomedicineMoraxella catarrhalisSignal TransductionEXPRESSIONPulmonary and Respiratory MedicineCD14BronchiRespiratory MucosaReal-Time Polymerase Chain ReactionOBSTRUCTIVE PULMONARY-DISEASETLRs NLR bronchial inflammationNLRDENDRITIC CELL SUBSETS03 medical and health sciencesProtein DomainsmedicineHumansTLRsAgedTOLL-LIKE RECEPTORSCOPD TLR4InflammationScience & TechnologyBacteriabusiness.industrymedicine.diseaseHaemophilus influenzaeBacterial Loadrespiratory tract diseasesToll-Like Receptor 4TLR2030104 developmental biology030228 respiratory systemImmunologyINNATE IMMUNITYT-CELLSbusinessThe European respiratory journal
researchProduct

The role of extracellular calcium in bone metastasis

2016

AbstractThis review summarizes the role of extracellular calcium, as found present in the bone tissue, in the process of bone metastasis.

0301 basic medicinelcsh:Diseases of the musculoskeletal systemIGF insulin-like growth factorPGE-2 prostaglandin E-2Bone tissueFibroblast growth factorM-CSF macrophage colony-stimulating factorPDGF platelet-derived growth factorBone remodelingSK3 small conductance calcium-activated potassium channel 30302 clinical medicineERK extracellular signal-regulated kinaseTGFβ transforming growth factor betaBMP's bone morphogenetic proteinsbiologyAKT AKT8 virus oncogene cellular homologBone metastasislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitiescAMP cyclic adenosine monophosphatemedicine.anatomical_structureOncologyRANKL030220 oncology & carcinogenesisIon channelsCaSR calcium-sensing receptorPTHrP parathyroid hormone-related proteinPlatelet-derived growth factor receptorResearch PaperTRP transient receptor potentialmedicine.medical_specialtychemistry.chemical_elementCalciumRANKL receptor activator of NF-κB ligandlcsh:RC254-28203 medical and health sciencesPLC phospholipase CInternal medicinemedicineExtracellularCaSRET-1 endothelin-1PTEN phosphatase and tensin homolog deleted on chromosome 10business.industryBone metastasismedicine.diseaseFGF fibroblast growth factor030104 developmental biologyEndocrinologyPSA prostate specific antigenchemistryCOPD chronic obstructive pulmonary diseasebiology.proteinCancer researchJNK jun N-terminal kinasePKA protein kinase ARANK receptor activator of NF-κBCalciumlcsh:RC925-935businessMAPK mitogen-activated protein kinaseJournal of Bone Oncology
researchProduct

Cigarette Smoke Increases Endothelial CXCL16-Leukocyte CXCR6 Adhesion In Vitro and In Vivo. Potential Consequences in Chronic Obstructive Pulmonary D…

2017

Cardiovascular disease (CVD) is a major comorbidity in chronic obstructive pulmonary disease (COPD). Although the mechanism of its development remains largely unknown, it appears to be associated with cigarette consumption and reduced lung function. Therefore, the aim of this study was to investigate the potential link between water-soluble cigarette smoke extract (CSE)-induced endothelial dysfunction and the function of CXCL16/CXCR6 axis on the initial attachment of leukocytes, in addition to its possible impact on COPD-associated systemic inflammation. To do this, we employed several experimental approaches, including RNA silencing and flow cytometry analysis, the dynamic flow chamber tec…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyChemokinecardiovascular comorbidityImmunologychemokines030204 cardiovascular system & hematologySystemic inflammationPeripheral blood mononuclear cellendothelial dysfunctionchronic obstructive pulmonary disease03 medical and health sciences0302 clinical medicineInternal medicinemedicineImmunology and AllergyPlateletEndothelial dysfunctionCXCL16Original ResearchCOPDbiologybusiness.industrycigarette smokearterial endotheliumleukocyte recruitmentmedicine.disease030104 developmental biologyEndocrinologybiology.proteinmedicine.symptombusinesslcsh:RC581-607Intravital microscopyFrontiers in Immunology
researchProduct

HSP60 activity on human bronchial epithelial cells

2017

HSP60 has been implicated in chronic inflammatory disease pathogenesis, including chronic obstructive pulmonary disease (COPD), but the mechanisms by which this chaperonin would act are poorly understood. A number of studies suggest a role for extracellular HSP60, since it can be secreted from cells and bind Toll-like receptors; however, the effects of this stimulation have never been extensively studied. We investigated the effects (pro- or anti-inflammatory) of HSP60 in human bronchial epithelial cells (16-HBE) alone and in comparison with oxidative, inflammatory, or bacterial challenges. 16-HBE cells were cultured for 1–4 h in the absence or presence of HSP60, H2O2, lipopolysaccharide (…

0301 basic medicinep38αSettore BIO/17 - IstologiaLipopolysaccharidep38 mitogen-activated protein kinasesImmunologyStimulationBronchip38 Mitogen-Activated Protein KinasesERK1Cell LinePathogenesisMitochondrial Proteins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOriginal Research ArticlesHumansImmunology and AllergyCOPDInterleukin 8Protein kinase AReceptor16-HBE; COPD; CREB1; ERK1; HSP60; IL-10; IL-8; JNK1; MyD88; NF-κB p65 subunit; TLR-4; p38αPharmacologyIL-8Settore BIO/16 - Anatomia UmanaInterleukin-8JNK1NF-κB p65 subunitEpithelial CellsTLR-4Chaperonin 60MyD88Interleukin-1016-HBEToll-Like Receptor 416-HBE; COPD; CREB1; ERK1; HSP60; IL-10; IL-8; JNK1; MyD88; NF-κB p65 subunit; p38α; TLR-4; Immunology and Allergy; Immunology; PharmacologyInterleukin 10030104 developmental biologychemistry030220 oncology & carcinogenesisIL-10Cancer researchCREB1NF-κB p65 subunitHSP60p38α
researchProduct

Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

2019

Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial…

3003AgonistDrugAlginatesCell Survivalmedicine.drug_classmedia_common.quotation_subjectSodium alginate polymerPharmaceutical ScienceChronic obstructive pulmonary disease (COPD)Inflammation02 engineering and technologyPharmacology030226 pharmacology & pharmacyCell LinePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinecAMPmedicineHumansAerodynamic diameterAdrenergic beta-2 Receptor AgonistsSalmeterol Xinafoatemedia_commonDrug CarriersCOPDInhalationChemistryTherapeutic effectAdhesiveness021001 nanoscience & nanotechnologymedicine.diseaseLipidsSALMETEROL XINAFOATEBronchodilator Agentsrespiratory tract diseasesSalmeterol Xinafoate (SX)MucusAerodynamic diametermedicine.symptom0210 nano-technologyInternational Journal of Pharmaceutics
researchProduct

ROLE OF SMADS IN REMODELLING OF THE LARGE AIRWAYS IN PATIENTS WITH COPD.

2011

AIRWAYSSettore BIO/16 - Anatomia UmanaCOPDSMADS
researchProduct

Do ventilatory parameters influence outcome in patients with severe acute respiratory infection? Secondary analysis of an international, multicentre1…

2021

Purpose: To investigate the possible association between ventilatory settings on the first day of invasive mechanical ventilation (IMV) and mortality in patients admitted to the intensive care unit (ICU) with severe acute respiratory infection (SARI). Materials and methods: In this pre-planned sub-study of a prospective, multicentre observational study, 441 patients with SARI who received controlled IMV during the ICU stay were included in the analysis. Results: ICU and hospital mortality rates were 23.1 and 28.1%, respectively. In multivariable analysis, tidal volume and respiratory rate on the first day of IMV were not associated with an increased risk of death; however, higher driving pr…

ARDSSoins intensifs réanimationmedicine.medical_treatmentAirway pressuresPEEP positive end-expiratory pressureCritical Care and Intensive Care Medicinelaw.inventionHypoxemiaCohort StudiesPositive-Pressure RespirationMechanical ventilationSARI severe acute respiratory infectionlawHospital MortalityProspective StudiesIQR interquartile rangesProspective cohort studyRCT randomized controlled trialTidal volumeSOFA Sequential Organ Failure AssessmentSAPS Simplified Acute Physiology ScoreIntensive care unitVCV volume-controlled ventilationHIV human immunodeficiency virusIntensive Care UnitsIC GLOSSARI Intensive Care Global Study on Severe Acute Respiratory Infectionmedicine.symptomCohort studyLOS length of staymedicine.medical_specialtyVt tidal volumeCOPD Chronic obstructive pulmonary diseaseNYHA New York Heart Association.PCV pressure-controlled ventilationArticleInternal medicineICU Intensive Care UnitSIMV Synchronized intermittent mandatory ventilationmedicineTidal VolumeHumansDP driving pressurePEEPARDS acute respiratory distress syndromeMechanical ventilationbusiness.industryOdds ratioPneumoniaPlateau pressuremedicine.diseaseRespiration ArtificialVILI ventilator induced lung injuryCI confidence intervalOR odds ratioIMV invasive mechanical ventilationCPAP continuous positive airway pressureARDSbusinessSD standard deviationECMO extracorporeal membrane oxygenationPBW predicted body weightPplat plateau pressure
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?

2013

<b><i>Background and Objective:</i></b> We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). <b><i>Methods:</i></b> Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV<sub>1</sub>) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and …

AdultLung DiseasesMalePulmonary and Respiratory Medicinemedicine.medical_specialtyMEDLINEPulmonary diseaseComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionCohort StudiesPulmonary Disease Chronic ObstructiveRandomized controlled triallawForced Expiratory VolumeInternal medicinePragmatic Clinical Trials as TopicmedicineHumansCOPDAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overCOPDbusiness.industryPatient SelectionSmokingAge FactorsOxygen Inhalation TherapyRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityBronchiectasisrespiratory tract diseasesPhysical therapyFemaleObservational studyCognition DisordersbusinessCohort study
researchProduct

The difference in risk of chronic pulmonary disease morbidity and mortality between former elite athletes and ordinary men in Finland.

2019

The impact of a history of competitive sports on later smoking behaviour and occurrence of chronic pulmonary diseases is poorly known. We investigated how a history of elite level sports predicted later pulmonary disease morbidity and mortality. Chronic pulmonary disease incidence was assessed from national hospital and cause-of-death registers from 1970 to 2015 among Finnish male former elite athletes (n = 2078) and matched controls (n = 1453) alive in 1970 (mean age 45.0 years). Hazard ratios (HRs) were calculated by Cox proportional hazards model. In 1985, cohort members reported on their smoking habits, engagement in physical activity/sports and physician-diagnosed chronic diseases. The…

AdultLung DiseasesMalemedicine.medical_specialtyChronic bronchitisCompetitive Behavior030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationComorbidity03 medical and health sciences0302 clinical medicineAge DistributionRisk FactorsInternal medicineCause of DeathmedicineHumansOrthopedics and Sports MedicineLongitudinal StudiesYoung adultExerciseFinlandProportional Hazards ModelsCOPDbiologyAthletesProportional hazards modelbusiness.industryHazard ratioSmoking030229 sport sciencesGeneral MedicineLength of StayMiddle Agedbiology.organism_classificationmedicine.disease3. Good healthSocioeconomic FactorsAthletesCohortChronic DiseasePhysical EndurancebusinessCohort studyEuropean journal of sport science
researchProduct